Video

GenesisCare physicians discuss PSMA-PET imaging agent Pylarify

GenesisCare doctors Kishore K. Dass, MD, Anurag Agarwal, MD, and Jerry Singer, MD, share their expert insight on the novel PSMA-PET imaging diagnostic Pylarify (piflufolastat F 18), which is FDA approved for use in patients with prostate cancer. The first US patient to receive Pylarify was treated at the GenesisCare facility in Boca Raton, Florida, where these doctors work.

Related Videos
Related Content
FDA grants Fast Track Designation to RAG-01 in NMIBC
May 21st 2024

FDA grants Fast Track Designation to RAG-01 in NMIBC

Hannah Clarke Jason M. Broderick
RAG-01 is an saRNA therapy that is delivered via intravesical instillation and is designed to target and activate p21, a tumor suppressor gene.
Novel small activating RNA therapy explored in NMIBC
April 12th 2024

Novel small activating RNA therapy explored in NMIBC

Jason M. Broderick
The study is exploring the small activating RNA therapy RAG-01 in patients with BCG-unresponsive non–muscle-invasive bladder cancer.
Phase 3 study launches exploring TLX591 in mCRPC
November 13th 2023

Phase 3 study launches exploring TLX591 in mCRPC

Hannah Clarke
The ProstACT GLOBAL study is investigating second-line TLX591 in combination with the current standard of care (SOC) vs SOC alone in patients with mCRPC who have progressed on a novel androgen axis drug.
Radio–antibody drug conjugate elicits antitumor activity in PSMA-positive mCRPC
October 19th 2023

Radio–antibody drug conjugate elicits antitumor activity in PSMA-positive mCRPC

Jason M. Broderick
Treatment with TLX591 resulted in a PSA reduction in nearly two-thirds of evaluable patients with PSMA-expressing metastatic castration-resistant prostate cancer.
Study launches of novel PSMA-targeting antibody in biochemically recurrent prostate cancer
September 27th 2022

Study launches of novel PSMA-targeting antibody in biochemically recurrent prostate cancer

Jason M. Broderick
The phase 2 ProstACT TARGET study is exploring TLX591 (177Lu-DOTA-rosopatamab) in combination with external beam radiation therapy.
GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial
February 11th 2022

GenesisCare Enrolls First Patients to SpaceOAR Vue Hydrogel Global Clinical Trial

GenesisCare
For the first time, the trial will examine the efficacy of SpaceOAR Vue Hydrogel in reducing late gastrointestinal toxicity and improving the quality of life in patients receiving stereotactic body radiotherapy for the treatment of prostate cancer.
© 2024 MJH Life Sciences

All rights reserved.